Eurofins Viracor Announces New Lenexa Facility For its BioPharma Services

Posted September 3, 2025

Eurofins Viracor plans to build a custom-built 96,000 square foot facility at its Lenexa headquarters for its biopharmaceutical division.

The new facility is scheduled for completion in September, according to a release. In 2020, Eurofins Viracor BioPharma Services was formally spun out of Eurofins Viracor. The ladder focuses on supporting biopharmaceutical sponsors with specialized analytical and clinical trial services.

Eurofins Viracor first moved into its Lenexa headquarters, located at 18000 W. 99th St., in February 2022. Before that, Eurofins Viracor was based in Lee’s Summit. The new facility will be located “only a few miles from its previous location,” according to the release. 

The two companies previously operated out of the same facility; however, this new facility will allow Eurofins Viracor BioPharma to have dedicated space to concentrate on its core market. The two companies can now take full advantage of the Kansas City region’s strategic benefits, including access to scientific talent, centralized logistics, and a thriving life sciences sector.

For Eurofins Viracor BioPharma, the new facility supports the increasing demand for advanced testing services, particularly in sequencing and precision medicine, cell-based assays, high-complexity flow cytometry, vaccine development and biomarker analysis.

The expanded infrastructure will also enhance BioPharma’s ability to support custom assay development, GLP/GCLP-compliant assay validation, and clinical sample testing across all phases of drug development, as well as provide space for future service line launches.